Accrual speed and characteristics of phase III U.S. cancer clinical trials with frequently used biomarkers in eligibility criteria.
475 Background: Patient accrual remains a key rate-limiting step in cancer clinical trials, often influencing statistical power, trial budgets, and delayed access to therapies. In particular, trials involving biomarker measurement may have accrual concerns related to the additional screening procedures in suppo...